Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy

NCT05929651 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningococcal Immunisation
Healthy Volunteers

Interventions

BIOLOGICAL: MenACYW conjugate vaccine

Sponsor

Sanofi Pasteur, a Sanofi Company